Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

European Journal of Haematology

Volumn 85, Issue 5, 2010, Pages 430-438

  Kolnagou, Annita ^a,b   Kleanthous, Marios ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

^b Paphos General Hospital   (Cyprus)

Author keywords

Chelation therapy; Combination therapy; Deferiprone; Deferiprone monotherapy; Deferoxamine; Dose protocol, transfusion; Iron normalisation; Iron overload; Optimal therapy

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADULT; AGED; ARTICLE; CHELATION THERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MONITORING; FEMALE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HUMAN; IRON CHELATION; IRON STORAGE; LIVER FUNCTION; MAINTENANCE THERAPY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T WAVE; THALASSEMIA;

ADULT; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PYRIDONES; SIDEROPHORES; THALASSEMIA; TREATMENT OUTCOME;

EID: 78049273304     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01499.x     Document Type: Article

References (45)

1. World Health Organisation. Community control of hereditary anaemias. WHO Bull 1983;61:63-80.
2. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Meleventi C, Di Gregorio F, Buratini MG, Terzoli S, Gabutti V. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-9.
3. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004;73:359-66.
4. Kyriacou K, Michaelides Y, Senkus R, Simamonian K, Pavlides N, Antoniades L, Zambartas C. Ultrastructural pathology of the heart in patients with β-thalassaemia major. Ultrastruct Pathol 2000;24:75-81.
5. κolnagou A, Michaelides Y, Kontos Ch, Kyriacou K, Kontoghiorghes GJ. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassaemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin 2008;32:17-28.
6. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK register. Lancet 2000;355:2051-2.
7. Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93:741-52.
8. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem 2005;12:2663-81.
9. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
10. Borgna-Pignatti C, Cappellini MD, De Stefano Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
11. Mavrogeni SI, Gotsis ED, Markussis V, Tsekos N, Politis C, Vretou E, Kremastinos D. T2 relaxation time study of iron overload in β-thalassemia. MAGMA 1998;6:7-12.
12. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
13. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion dependent thalassemia and sickle cell disease. Blood 2004;103:1934-6.
14. Kolnagou A, Eracleous E, Economides Ch, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting excess cardiac iron loading and increase the risk of cardiomyopathy in thalassaemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2. Hemoglobin 2006;30:219-27.
15. Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, Caocci G, Agus A, Angelucci E. Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Heamatologica 2008;9:1385-8.
16. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 2006;115:106-8.
17. Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2 or T2 for preventing heart disease in thalassaemia. Br J Haematol 2004;127:360-1.
18. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2 cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
19. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem 2005;12:2695-709.
20. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008;32:1-15.
21. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002;360:516-20.
22. Telfer P, Coen PG, Christou M, et al. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-92.
23. Kontoghiorghes GJ. Advances in oral iron chelation in man. Int J Haematol 1992;55:27-38.
24. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and deferoxamine. Br J Haematol 1998;103:361-4.
25. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin 2006;30:239-49.
26. Tanner MA, Galanello R, Dessi C, et al. A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84.
27. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 2003;88:1423-5.
28. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassaemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 2008;32:41-7.
29. Sheppard L, Kontoghiorghes GJ. Competition between L1, desferrioxamine and other chelators for iron and the effect of other metal ions on iron binding. Arzn Forsch/Drug Research 1993;43:659-63.
30. Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 2006;30:183-200.
31. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 2003;43:565-72.
32. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44.
33. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79:2741-8.
34. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990;48:255-61.
35. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004;83:471-3.
36. Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in β-thalassaemia. Hemoglobin 2008;32:29-34.
37. Aessopos A, Kati M, Farmaki D, Polonifi E, Deftereos S, Tsironi M. Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Haematol 2007;86:212-5.
38. Agarwal MB. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1). Indian J Pediatr 1993;60:509-16.
39. Morales NP, Yamanont P, Jirasomprasert T, Wilairat P, Chantharaksri U, Chuncharunee S, Fucharoen S. Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. Int J Clin Pharmacol Ther 2009;47:358-64.
40. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110:401-8.
41. Rajapurkar MM, Alam MG, Bhattacharya A, Shah SV. Novel treatment for diabetic nephropathy. J Am Soc Nephrol 2007;18:329A.
42. Rajapurkar MM, Radhakrishne B, Shah SV. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 2007;18:57-8A.
43. Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci 2009;E1:161-78.
44. Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf 2010;9:201-6.
45. Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008;120:123-8.